BOSTON, MA / ACCESSWIRE / March 8, 2021 / Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it is investigating Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) for potential violations of the federal securities laws.
After the markets closed on March 8, 2021, Acadia announced that on March 3, 2021, the FDA informed Acadia, as part of the FDA's ongoing review of Acadia's supplemental New Drug Application, that the FDA had "identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time." On this news, shares have fallen precipitously in after-market trading.
Block & Leviton LLP (www.blockleviton.com) is investigating whether Acadia and certain of its executives may be liable for securities fraud. If you purchased or acquired shares of Acadia and have questions about your legal rights or possess information relevant to this investigation, please contact Block & Leviton attorneys at (617) 398-5600, via email at [email protected], or visit our website for information on the case.
Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
SOURCE: Block & Leviton LLP